Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AGE precursor molecules are chemically reactive species—including reducing sugars (glucose, fructose) and dicarbonyl compounds (such as methylglyoxal and glyoxal)—that initiate the non-enzymatic glycation of proteins, lipids, and nucleic acids in living organisms. These molecules react via the Maillard reaction to form unstable intermediates (Schiff bases and Amadori products), eventually leading to the irreversible formation of Advanced Glycation End Products (AGEs). AGE precursors play a critical role in metabolic and age-related diseases by driving the accumulation of AGEs, which are implicated in tissue cross-linking, inflammation, and cellular dysfunction. However, the molecules themselves are not directly considered therapeutic targets; rather, prevention of their accumulation or promotion of their detoxification (via enzymes or small molecule scavengers) is a focal point of pharmacological research.
Small-molecule scavenging or trapping of precursor reactive carbonyls (e.g., aminoguanidine binds methylglyoxal) Enzymatic detoxification (e.g., glyoxalase pathway) Limiting precursor availability through dietary or metabolic interventions
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AGE precursor molecules.